Jaguar Health announced that Jaguar family company Napo Pharmaceuticals has initiated the commercial launch of the FDA-approved oral mucositis prescription product Gelclair in the U.S. Napo’s core target audiences for the Gelclair launch are patients with head and neck cancer and oncology-focused health care practitioners. As part of the ongoing Gelclair launch, Napo plans to exhibit at several key oncology conferences in the coming months, and there will also be a strong digital marketing component to the launch, targeting health care providers and providing information and education for patients to self-advocate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar submits abstract for study of impact of diarrhea from cancer therapies
- Jaguar Health announces completed analysis from Phase 3 OnTarget trial
- Jaguar Health celebrates National Service Dog Month
- Jaguar Health announces patent issued in Jordan for SBS treatment
- Jaguar Health’s Napo Pharmaceuticals issues Hong Kong patent for SBS treatment